Novartis Bullish About Prexige; Anticipates Blockbuster Potential
This article was originally published in The Pink Sheet Daily
Executive Summary
Company takes a more bullish stance on its COX-2 inhibitor than Merck, which has assumed FDA approval of its Vioxx follow-on product Arcoxia in 2007.